Blocking interleukin-1β in acute and chronic autoinflammatory diseases.
about
Shear stress modulation of IL-1β-induced E-selectin expression in human endothelial cellsA model for lupus brain diseaseIL-1 receptor 2 (IL-1R2) and its role in immune regulationUric acid, hyperuricemia and vascular diseasesThe role of the T cell in age-related inflammationNLRP3 inflammasome activation in murine alveolar macrophages and related lung pathology is associated with MWCNT nickel contaminationDevelopment of autoimmune hair loss disease alopecia areata is associated with cardiac dysfunction in C3H/HeJ miceGene expression profiling of transporters in the solute carrier and ATP-binding cassette superfamilies in human eye substructures.Potential of IL-1, IL-18 and Inflammasome Inhibition for the Treatment of Inflammatory Skin Diseases.Gaucher iPSC-derived macrophages produce elevated levels of inflammatory mediators and serve as a new platform for therapeutic development.Sustained delivery of IL-1Ra from PF127-gel reduces hyperglycemia in diabetic GK-rats.Interleukin-1β downregulates RBP4 secretion in human adipocytes.Current state of type 1 diabetes immunotherapy: incremental advances, huge leaps, or more of the same?Analysis of mechanical ventilation and lipopolysaccharide‑induced acute lung injury using DNA microarray analysis.Assessment of proliferating cell nuclear antigen and its relationship with proinflammatory cytokines and parameters of disease activity in multiple myeloma patientsComprehensive analysis of tumor microenvironment cytokines in Waldenstrom macroglobulinemia identifies CCL5 as a novel modulator of IL-6 activityER stress activates the NLRP3 inflammasome via an UPR-independent pathway.NF-κB is the transcription factor for FGF-2 that causes endothelial mesenchymal transformation in corneaDeficiency of myotubularin-related protein 14 influences body weight, metabolism, and inflammation in an age-dependent manner.Single-cell protein secretomic signatures as potential correlates to tumor cell lineage evolution and cell-cell interaction.IL-1β processing in mechanical ventilation-induced inflammation is dependent on neutrophil factors rather than caspase-1IL-1β, RAGE and FABP4: targeting the dynamic trio in metabolic inflammation and related pathologies.Inhibition of p38 mitogen-activated protein kinase impairs influenza virus-induced primary and secondary host gene responses and protects mice from lethal H5N1 infection.Zebrafish tissue injury causes upregulation of interleukin-1 and caspase-dependent amplification of the inflammatory response.Molecular basis of applied biological therapeutics.The potential role of interleukin-17 in severe asthmaAnti-inflammatory mediators as physiological and pharmacological regulators of parturition.Interleukin-1 and stroke: biomarker, harbinger of damage, and therapeutic target.Blocking interleukin-1 as a novel therapeutic strategy for secondary prevention of cardiovascular events.Current status of inflammasome blockers as anti-inflammatory drugs.Caspase-1: is IL-1 just the tip of the ICEberg?Role of inflammatory mechanisms in pathogenesis of type 2 diabetes mellitus.Role of interleukin-1 inhibitors in the management of gout.How should we approach classification of autoinflammatory diseases?The Charcot foot as a complication of diabetic neuropathy.Role of inflammasomes in intestinal inflammation and Crohn's disease.The inflammasome and IL-1β: implications for the treatment of inflammatory diseases.Regulating against the dysregulation: new treatment options in autoinflammation.Analgesic, anti-inflammatory and anti-pyretic activities of Caesalpinia decapetala.Acidosis drives damage-associated molecular pattern (DAMP)-induced interleukin-1 secretion via a caspase-1-independent pathway.
P2860
Q21134771-6725938C-3594-4D35-BAEC-EED41BD00DAEQ26824461-D35E8256-1F32-462D-8188-D9C26C14241DQ26826872-219EC2DE-5CFD-4706-99A0-11FB64848F47Q26850727-A0F9A0AF-94DE-4C25-AA4C-F8BA0E56BEB1Q27026492-F342B7A6-A379-4332-B4CA-E064FEE5DFBAQ28389971-23616072-59FB-4D6B-982D-68FABEB059B6Q28487124-581EDF0D-955B-4B8D-8FE4-D36558AE9FF5Q33654708-12E84C2F-1722-4FD8-AF4D-F2249FFDFBA2Q33710807-EE97DAA2-8788-4025-965B-97D9458E4819Q34066863-BD935E12-91D8-403C-90E9-6D45656E5B01Q34586474-174975D2-35C6-47CA-9B54-C34A86F64F6CQ34608842-F097DE15-B0D0-487A-BAB2-74565231F7C0Q35116303-5814F19C-7198-49F0-AC1B-67BCA9FB1FD7Q35387806-D09AE083-F7A3-4AE6-905C-12AE56D6C471Q35466987-FDAE897B-7977-490F-AD74-B0B2CD8E28F9Q35553334-8A7BE2DD-6BB0-49D4-A086-53CA6E37BD86Q35723848-87316353-6ED6-4A01-AB54-4EC79CF4C56EQ35921468-9C1D8C94-01DF-49FF-B7F1-B0993F22BCD4Q36393696-98B062E1-C148-4766-93C1-1E191D963061Q36589648-01F96059-352C-4A7E-A13D-8DB449803C6DQ36702336-A9CA8BB3-BE93-4C64-B5D8-A7834D580B52Q37305013-FC59C2B1-3A4C-46B7-BEA9-93C5424454C7Q37428595-F5C35C0A-6F64-43E2-BFCC-F062A1CDEBD9Q37566128-27AB81F8-1E98-4116-B7B6-A48BF053816DQ37825467-1890729A-7F9E-4F42-A271-418E0404B8F5Q37902959-0C9BDD7A-25DE-4A87-9BF4-7625A4974D52Q37927081-ECF79E82-2B66-48A8-9283-3A6EB23F3D50Q37959134-1C4770E2-D288-413B-A3EB-0E0FC98EDF96Q38008700-7C7E76E2-F06D-46FC-97E7-0968942231CFQ38011774-6ECAD4B8-55FE-496A-872E-0A4C0304F688Q38024075-3568DF2A-F7B5-412E-AA0C-2D56010A7735Q38044705-0188BEB4-47C5-4407-91E4-1E7E4C0ECC63Q38095844-E3BDE7B3-6FA9-49AB-8AC5-98E36CFA70C7Q38120387-7268952A-76F8-4C7B-8047-C54AA8218667Q38263708-1BA5F6BA-D1FB-47CE-A97B-651BEC02E1C8Q38291767-1448F220-EDA8-42B8-9EBD-CC6D95FE87DFQ38389302-62A1F070-2F3E-4EBF-9D80-9C6E7DA609D6Q38522837-77C0CC1E-6561-443D-B40D-0F7A0613C5B1Q39082143-8B4545EC-5704-42D3-8CBD-8AAF9183ECBFQ39097629-D2BDD739-51F8-4F6C-89CA-CBCA95432C19
P2860
Blocking interleukin-1β in acute and chronic autoinflammatory diseases.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on January 2011
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Blocking interleukin-1β in acute and chronic autoinflammatory diseases.
@en
Blocking interleukin-1β in acute and chronic autoinflammatory diseases.
@nl
type
label
Blocking interleukin-1β in acute and chronic autoinflammatory diseases.
@en
Blocking interleukin-1β in acute and chronic autoinflammatory diseases.
@nl
prefLabel
Blocking interleukin-1β in acute and chronic autoinflammatory diseases.
@en
Blocking interleukin-1β in acute and chronic autoinflammatory diseases.
@nl
P2860
P1476
Blocking interleukin-1β in acute and chronic autoinflammatory diseases.
@en
P2093
C A Dinarello
P2860
P356
10.1111/J.1365-2796.2010.02313.X
P407
P577
2011-01-01T00:00:00Z